Showing results (81-90 of 102) with videos related to
Sort By:
Pageof 11
Annals of the New York Academy of Sciences|June 16, 2005
The chemistry and biology of human relaxin-3Geoffrey W Tregear, Ross A Bathgate, Sharon Layfield, et al.Frontiers in Pharmacology|March 29, 2021
Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart FailurePatricia Rueda, Jon Merlin, Stefano Chimenti, et al.Kidney International|January 17, 2014
Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosisBryna S Man Chow, Martina Kocan, Sanja Bosnyak, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 9, 2002
Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosisChrishan S Samuel, Chongxin Zhao, Ross A D Bathgate, et al.Analytical Biochemistry|December 19, 2016
High throughput, quantitative analysis of human osteoclast differentiation and activityNatalie A Diepenhorst, Cameron J Nowell, Patricia Rueda, et al.Endocrinology|January 6, 2007
Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytesXiao-lei Moore, Su-ling Tan, Chen-yi Lo, et al.Scientific Reports|June 9, 2017
ML290 is a biased allosteric agonist at the relaxin receptor RXFP1Martina Kocan, Mohsin Sarwar, Sheng Y Ang, et al.Molecular Pharmacology|November 20, 2016
Isoform-Specific Biased Agonism of Histamine H3 Receptor AgonistsDarren M Riddy, Anna E Cook, Natalie A Diepenhorst, et al.Journal of Medicinal Chemistry|January 30, 2016
Engineering of a Novel Simplified Human Insulin-Like Peptide 5 AgonistNitin A Patil, Richard A Hughes, K Johan Rosengren, et al.Neuropharmacology|October 26, 2018
Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonistsDarren M Riddy, Anna E Cook, David M Shackleford, et al.Pageof 11